Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ensartinib versus crizotinib in ALK-positive non-small cell lung cancer
2015-004147-40Phase 3Active
- Sponsor
- Xcovery
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Ensartinib with Crizotinib (2 arms). Primary endpoint: Progression-free survival. Started Jun 2016; status: active.
02
Drugs
ensartinibcrizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-004147-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004147-40.